By the Top Tier Newswire AI Desk · October 5, 2026 at 7:47 PM ET · reviewed against 3 wire stories
NOVAVAX INC (NVAX) is up +20.08% in the latest session. Our newswire has captured 3 stories on NVAX across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why NVAX stock is up today
Novavax Inc (NASDAQ:NVAX) shares surged 20.08% to $12.56 in a volatile session driven by news from Vaxcyte and renewed interest in Novavax’s role in the fall vaccination season. The stock opened with a small gap up and traded as high as $13.38 before closing near that level. The move reflects optimism around vaccine development and distribution efforts.
What Happened
Vaxcyte announced on Monday that its experimental pneumonia vaccine, VAX-31, met the primary endpoints of a late-stage study in adults aged 50 and older. This development has drawn attention to the broader vaccine sector and may have contributed to a favorable market view for Novavax. Separately, Sanofi is distributing the Nuvaxovid COVID-19 shot during the fall vaccination season, which has boosted Novavax shares as the licensor of the technology. The stock has risen sharply in response to these developments, outperforming other biotech names like Moderna and BioNTech.
Retail traders and market participants have also been circulating unconfirmed rumors suggesting favorable clinical data for Novavax’s Matrix-M adjuvant, which could support broader vaccine applications. These rumors, though unverified, have added momentum to the stock.
What The Data Shows
The stock opened at $10.53 and traded as low as $10.28 before climbing to a session high of $13.38. Trading volume reached 25.7 million shares, or 5.6 times the 3-month daily average. Call options saw heavy activity, with $5.9 million in call premium traded versus $171,000 in put premium. The stock is currently near its 52-week high of $11.97 and has printed 72 fresh 52-week highs on October 5, 2026.
What To Watch
Novavax does not have scheduled earnings in the near term. Traders should monitor the breadth of coverage and any new developments regarding the Nuvaxovid vaccine or Matrix-M data to gauge the sustainability of the recent rally.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NVAX · Oct 5 session (5-min) · +19.67% vs prior close · updated 8:59 PM ETAI sentiment, last 36h · averaged over 3 stories · 61/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoStocktwits NewsBULLISH 67Product/PR
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.
10h ago24/7 Wall St.BULLISH 67Product/PR
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.28, a move that stands well apart from its closest vaccine rivals and the broader sector. Checking […]
10h agoInvesting.com MarketsNEUTRAL 50General
Why is Novavax stock surging today?
Why is Novavax stock surging today?
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →